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Abstract 
Omega transaminase enzymes are proving to be of vital importance in the production of 
chiral amines for drug manufacturing due to their high stereoselectivity and 
regioselectivity reactions. Omega transaminases also possess another key feature that can 
make them more desirable than other transaminase enzymes in that they are able to utilise 
substrates lacking a carboxyl group.  
This project has purified several recombinant omega transaminases from the bacteria; 
Streptomyces avermitilis, Deinococcus geothermalis, Pseudomonas putida and 
Pseudomonas aeruginosa. Attempts have been made to crystallise the proteins in order to 
determine their structures. D. geothermalis omega transaminase failed to purify due to 
lack of binding to Nickel columns despite having a histidine tag. P. putida omega 
transaminase failed to produce any crystals in the crystal screens available. P. aeruginosa 
omega transaminase crystals, whose holoenzyme structure has already been solved, were 
soaked in pyruvate and also produced crystals from co-crystallisation experiments with 
pyruvate. These crystals however did not show sufficient electron density in the active 
site to determine if the substrate had bound. They did however diffract to 2.0 Å and 1.8 Å 
resolution respectively. Co-crystallisation experiments with P. aeruginosa omega 
transaminase and the inhibitor gabaculine were successful however to date they have 
failed to produce X-ray diffraction data that could be processed despite diffracting to high 
resolution. 
The S. avermitilis omega transaminase produced crystals that were shown to be 
disordered when they underwent X-ray diffraction. Differential scanning fluorometry was 
carried out to identify the optimal buffer for protein stability. This identified the current 
Tris pH 7.5 buffer to lead to a low thermodynamic stability of the protein. Several new 
buffers including MES at pH 6 were identified as being the most likely candidates for 
stabilising the protein and producing ordered crystals. 
Data collected from a Chromobacterium violaceum omega transaminase with a F89 to 
A89 mutation was successfully processed and refined. The resultant structure showed an 
increase in flexibility in the substrate carboxyl binding residue, R416, and an increase in 
space available for substrate binding. HPLC assays showed alpha-methylbenzylamine 
activity remained. An amino acid oxidase/horseradish peroxidase linked assay showed 
there to be a small increase in activity towards β-alanine due to this mutation. Further 
mutations will be necessary to enable this enzyme to utilise β-alanine at a more practical 
rate of conversion. 
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Abbreviations 
4-AAP    4-Aminoantipyrine 
AcornAT              Acetylornithine aminotransferase 
AlaAT     Alanine aminotransferase 
AP     Acetophenone 
APS     Ammonium persulfate 
AT      Aminotransferase 
AspAT     Aspartate aminotransferase 
BcaaAT    Branched chain amino acid aminotransferase 
Da                         Daltons 
DaaAT      D-amino acid aminotransferase 
D-alaAT                 D-alanine aminotransferase 
DapaAT                  7,8-Diaminopelargonic acid aminotransferase 
dd                           Double distilled 
EPPS                       4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid                    
GabaAT                   γ-Aminobutyric acid aminotransferase 
GF        Gel filtration 
HEPES                    4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HisPAT                    Histidinol-phosphate aminotransferase 
His-tag         Poly histidine tag 
IPTG                  Isopropyl β-D-galactopyranoside 
MBA         α-methylbenzylamine 
MES                        4-Morpholineethanesulfonic acid 
MOPS                     4-Morpholinepropanesulfonic acid 
mPMS        1-Methoxy-5-Methylphenazinium Methyl Sulfate 
MTT           3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAD        Nicotinamide adenine dinucleotide 
OrnAT        Ornithine aminotransferase 
PAGE                      Polyacrylamide gel electrophoresis 
PDB                         Protein Databank 
PheAT                      Phenylalanine aminotransferase 
PIPES                      1,4-Piperazinediethanesulfonic acid 
PLP         Pyridoxal-5’-phosphate 
PMP         Pyridoxamine phosphate 
PSerAT         Phosphoserine aminotransferase 
SDS                          Sodium dodecyl sulfate 
SerAT         Serine aminotransferase 
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TBHBA       2, 4, 6-Tribromo-3-hydroxybenzoic acid  
TEMED        N,N,N,N-tetramethylethylene diamide 
Tris         Tris[hydroxymethyl]aminomethane 
TyrAT         Tyrosine aminotransferase 
ω-AaAT                   ω-amino acid aminotransferase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
List of Contents 
 
Chapter 1 - Introduction 
1.1. Applications of Biocatalysis...…………………………………………………….7 
1.2. Transaminase Enzymes...………………………………………………………....8 
1.3. Transaminase Mechanism………………………………………………………...9 
1.4. Transaminase Classification……………………………………………………..11 
1.5. Omega Transaminase Specificity………………………………………………..12 
1.6. Omega Transaminase Structure………………………………………………….13  
1.7. Inhibition of Omega Transaminase……………………………………………...15 
1.8. Differential Scanning Fluorometry Theory……………………………………...17 
1.9. Previous Work Relevant To This Project  
 1.9.1. Structural Studies on Native Omega Transaminase…………………...18 
 1.9.2. Site Directed Mutagenesis of Omega Transaminase…………………..19 
1.10. Aims of Project.………………………………………………………………...20 
Chapter 2 - Materials and Methods 
2.1. Enzyme Purification 
2.1.1. Buffers....……………………………………………………………....22 
2.1.2. Bacteria Cultures and Storage…………………………………………23 
2.1.3. Lysing Cell Cultures…………………………………………………...23 
2.1.4. SDS-PAGE gels…………………………………………………....….24 
2.1.5. Purification of enzyme………………………………………………...25 
2.1.6. Nickel Chromatography……………………………………………….25 
2.1.7. Hydrophobic interaction Chromatography…………………………….25 
2.1.8. Ion exchange Chromatography………………………………………..25 
2.1.9. Gel Filtration Chromatography………………………………………..26 
2.2. Crystallisation Trials 
 2.2.1. Protein Concentration Determination………………………………….26 
2.2.2. Crystal Screening..…………………………………………………….27 
2.2.3. Crystal Soaks..…………………………………………………………27 
2.2.4. Co-crystallisation..………………………………………....………….28 
2.2.5. Crystal Optimisation..……………………………………....…………28 
2.2.6. Freezing Crystals..……………………………………………………..28 
 
 6 
2.3. Assays 
2.3.1. HPLC Assay.....………………………………………………………..29 
2.3.2. Tetrazolium Salt Based High-Throughput Assay……………………..30  
2.3.3. Amino Acid Oxidase/Horseradish Peroxidase Linked Assay…………30 
2.3.4. Differential Scanning Fluorometry..…………………………………..31 
2.4. Bioinformatics 
2.4.1. Multiple Sequence Alignment…………………………………………32 
2.4.2. Homology Modelling..………………………………………………...32 
2.4.3. X-ray Data Collection..………………………………………………..32 
2.4.4. Structural Refinement…………………………..……………………..32 
Chapter 3 - Results 
3.1. Protein Purification 
 3.1.1. Successful Purification Experiments…………………………………..33 
 3.1.2. Attempts at the Purification of D. geothermalis omega transaminase...37 
3.2. Protein Crystallisation and Structural Determination 
 3.2.1. Crystallisation Trials…………………………………………………..40 
 3.2.2. Crystal Soaks…………………………………………………………..43 
 3.2.3. Co-crystallisation Trials……………………………………………….43 
3.3. Structural Analysis 
 3.3.1. Multiple Sequence Alignment…………………………………………49 
 3.3.2. Homology Modelling Analysis………………………………………..51 
 3.3.3. Structural Refinement of Mutant C. violaceum omega transaminase…53 
3.4. Activity Assays………………………………………………………………….56 
3.5. Differential Scanning Fluorometry……………………………………………...58 
Chapter 4 – Discussion……………………………………………………………...62 
Chapter 5 - Conclusion 
5.1. Summary of Work……………………………………………………………….65 
5.2. Future Work.…………………………………………………………………….66 
5.3. Acknowledgements.……………………………………………………………..66 
References…………………………………………………………………………...67 
 
 
 
 7 
Chapter 1 - Introduction 
1.1. Applications of Biocatalysis 
Recently enzymes are being utilized as biocatalysts in a myriad of industrial processes 
for their high specificity, consistent results and, unlike tradition manufacturing 
materials, usually involving high temperatures, high pressures, toxic transition metals 
or a combination of the three, are reusable and can be highly stereoselective [1]. 
Examples of biocatalytic processes include the breakdown of amides by penicillin 
acylase, hydrolysis of esters to acids by esterases and lipases, the formation of malic 
acid by condensation by fumarase, conversion of glucose to fructose by glucose 
isomerase and the removal of a halogen by dehalogenases [2]. Many semi-synthetic 
antibiotics are now being made by utilising biocatalysis instead of chemical 
conversions based on stoichiometry. α-amino acid ester hydrolase, α-acylamino-β-
lactam acylhydrolase and ampicillin acylase are all enzymes that have been reported 
capable of producing semi-synthetic cephalosporins from 7-aminocephem or 6-
aminopenam with α-amino acid esters [3]. The immobilized enzyme penicillin acylase 
is being used in the manufacturing process of β-lactam antibiotics. Condensation of 6-
aminopenicillanic acid with D-(−)-4-hydroxyphenylglycine or D-(−)-phenylglycine 
by this enzyme will make amoxicillin or ampicillin respectively. Also cefadroxil and 
cephalexin can be made from 7-aminodesacetoxycephalosporanic acid in the same 
manner [4]. Whole cells can be used in complex reaction pathways that require 
regeneration of co-factors for the enzymes as it is far easier and cheaper to allow a 
living cell to do all the work in ensuring the enzyme remains active [1]. Due to their 
high specificity, there are few by-products of enzyme based reactions which with 
increasing environmental awareness becomes even more of a necessity as any waste 
must be dealt with properly, so the less there is the cheaper the end product. This 
specificity translates into the chirality of the end product which in drug manufacturing 
is vital as demonstrated by the dispute over a failed drugs test in the 2002 winter 
Olympics. Alain Baxter tested positive for amphetamines and subsequently lost his 
bronze medal, caused by a Vick's nasal spray which contained a legal isomer, L-
methamphetamine, of the banned drug D-methamphetamine, which shows how much 
biological interactions rely upon chirality [5]. In a review by Ramesh N. Patel 2002 
[6], the importance of chiral intermediates for drug manufacturing is highlighted with 
examples such as chiral amino acid intermediates for the production of β3-Receptor 
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agonists by an amidase from Mycobacterium neoaurum. HIV protease inhibitors are 
effective in combating retroviral infection. One of their synthesis steps requires the 
transamination of 1-keto-2-hydroxyindan to cis-1-amino indanol as shown in Fig 1.1. 
[6]. Production of inhibitors for matrix metalloprotease also require optically pure 
intermediates. These are used for the treatment of both cancer and rheumatic 
inflammation [7]. 
 
Fig. 1.1. Synthesis pathway of HIV protease inhibitor including the transamination reaction 
modified from Patel, 2002 [6]. 
 
1.2. Transaminase Enzymes - Background 
Transaminases (aminotransferases) traditionally have been used as an indicator in 
medical tests for liver disease to determine how much cell death is occurring within 
the liver. This has been useful in diagnosing hepatitis infection and liver disease from 
factors such as excessive alcohol consumption. It is also vital in the glucose-alanine 
cycle where transamination of pyruvate into alanine in the muscles for transport in the 
blood to the liver where it is converted back into pyruvate and then into glucose to be 
used by the energetically active muscle cells. Lately however transaminases are being 
seen as useful biocatalysts in industrial processes to manufacture optically pure 
amines. As their name suggests, they transfer amino groups from a donor containing 
an amine group, to a ketone acceptor which is the method by which the body creates 
what is known as the 'non-essential amino acids'.  
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Recently a transaminase was designed by Merck and Codexis for the production of 
sitagliptin, the active component of Januvia which is used in the treatment of type 2 
diabetes [8]. Prior to its development, sitagliptin was produced by enamine formation, 
followed by asymmetric hydrogenation at 250 pounds per square inch with a 
rhodium-based catalyst. This resulted in a mixture of sitagliptin at 97 % enantiomeric 
excess with a trace of rhodium. Recrystallisation was needed to improve the 
enantiomeric excess followed by addition of H3PO4 to produce sitagliptin phosphate. 
Homology modelling of the transaminase was used for the initial hypothetical library 
designs. Docking studies showed the (R)-selective transaminase ATA-117 to be 
incapable of binding the prositagliptin ketone due to steric interference in the small 
binding pocket and undesired interactions in the large binding pocket. Directed 
evolution was used along with substrate walking and point mutations based on the 
model to produce an enzyme containing a total of 27 mutations that was capable of 
the amination of prositagliptin ketone to sitagliptin at 99.95 % enantiomeric excess 
thereby removing the need for a rhodium catalyst and high pressure in the reaction 
step. Also recrystallisation is no longer required as it is already enantiopure [8]. This 
is a prime example of how transaminases and knowledge of their structure can prove 
useful in the pharmaceutical market. For this Merck and Codexis were awarded the 
Greener Reaction Conditions award in 2010.  
 
1.3. Transaminase Mechanism 
The co-factor for transaminase enzymes is pyridoxal-5’-phosphate (PLP), known as 
vitamin B6. It is used in a variety of catalytic reactions apart from transamination 
including decarboxylation and racemization. PLP enzymes are so versatile that it is 
estimated that 1.5 % of the total open reading frames in bacterial genomes encodes 
PLP dependant enzymes [9]. The enzyme forms an internal aldimine with the ε-amino 
group of a lysine in the active site and is capable of accepting electrons from the 
substrate. During the enzyme-substrate complex reaction (Fig. 1.2.) the lysine is 
replaced by the amino group of the amino donor which then forms an external 
aldimine [10]. Dunathan [11] hypothesised that the next step in the reaction was 
dependant upon which of the three bonds to the α carbon were cleaved, the scissile 
bond of the external aldimine has to be perpendicular to the plane of the π system 
bond between the coenzyme and the donor due the low activation energy of this 
particular configuration, forming a carbanion intermediate. The α-hydrogen is then 
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taken away from the amino acid donor to form a planar intermediate before being 
transferred to the C4 atom of the PLP molecule. The intermediate is then hydrolysed 
to pyridoxamine 5-phosphate (PMP) and a keto acid. The second step of the reaction 
involving the amino acceptor keto acid and the regeneration of PLP involves the exact 
same process working backwards [12]. It is agreed that the mechanism of 
transaminase reaction is by the 'bi ping-pong' system. Aspartate aminotransferase has 
been studied in more detail than any other transaminase and provides a good example. 
Its substrates and products oxaloacetate, aspartate, 2-oxoglutarate and glutamate bind 
to the enzyme through binding between Arg-386 and Arg-292 and their α- and ω- 
carboxyl groups via salt bridges and hydrogen bonding [13].  
 
Fig. 1.2. The transamination reaction involving pyridoxal-5’-phosphate cofactor and its 
intermediates modified from Soda, 2000 [12].  
 
 
 
 
 
 
  
 
  
Internal aldimine 
Replaced by amino donor  α carbon bond cleaved 
Scissile bond 
perpendicular to 
the π system  
α hydrogen lost from 
amino donor 
Planar intermediate 
Hydrolysed to a keto 
acid and PMP Hydrogen transferred to C4 of PLP 
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1.4. Transaminase Classification 
The transaminases can be split up into four sub-groups, according to Mehta et al 
(1993) [14] by comparing sequence homology, predicted secondary structure and 
hydropathy patterns for all the transaminase enzymes known at the time (Table 1.1). 
Sub-group I contains the transaminases AspAT, AlaAT, TyrAT, HisPAT and PheAT 
and overall this group seems to have a preference for 2-oxoglutarate as the keto acid 
substrate. Group III contains D-AlaAT and BcaaAT and both exhibit a preference for 
2-oxoglutarate as the keto acid substrate. D-AlaAT is a necessary enzyme for any 
bacteria possessing a cell wall as it is the mechanism by which D-alanine and D-
glutamate are made which are important cell wall components [15]. Group IV 
includes SerAT and PSerAT and they use L-serine and 3-phospho-L-serine as amino 
acid donors respectively. However it is the group II that this project will be focusing 
on, containing members such as AcornAT, OrnAT, ωAaAT, GaBaAT and DapaAT 
which are known as omega-aminotransferases [14]. These are so called due to the fact 
that during the first half of the reaction there is a transfer of an amino group to the 
position distant to the α carbon. This will always occur even when there is the option 
of selecting a second amino group on the α group with the same configuration, 
although during the second half reaction there is an α-transamination like most other 
aminotransferases [16] [17].  
 
Mehta sub-groups Transaminase Members Pfam sub-groups 
I Aspartate + Aromatic transaminase I + II 
II Omega transaminase III 
III Branched chain transaminase IV 
IV Phosphoserine transaminase V 
- ArnB transaminase VI 
Table 1.1. Comparison between the Pfam and Mehta sub-groups. The main transaminase 
members for each group are listed in the second column with the assigned groups from Mehta 
[14] in the first column and from Pfam in the third [14][18][19]. Mehta subgroups I, III and 
IV (Pfam subgroups I, II, IV, V and VI) are classified as alpha transaminases which catalyse 
amino donors with an adjacent carboxyl group. Mehta subgroup II (Pfam subgroup III) are 
classified as omega transaminases, which do not necessarily require a carboxyl group on the 
amino donor. 
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Recently, transaminase enzymes have been reclassified into six sub-groups according 
to their structure by the Pfam database [18].  All sub-groups of transaminases belong 
to the same fold family. The exception to this is group IV, which belongs to a 
different fold family and includes members such as branched chain transaminases. 
Omega transaminases were assigned to group III, while alpha transaminases were 
assigned to the other five groups. Aspartate and aromatic transaminases were assigned 
to groups I and II. Phosphoserine transaminases were assigned to group V and ArnB 
transaminases were assigned to group VI [19].  
 
1.5. Omega Transaminase Specificity 
Unlike all previously mentioned subgroups of transaminases, these can catalyse a 
reaction between a keto acid and an amino donor with the absence of a carboxyl 
group from the latter, giving rise to more options for biocatalysis. Vibrio fluvialis 
JS17 possesses a novel omega transaminase which has been under much investigation 
and has shown it to have broad substrate specificity and it has high selectivity for (S)-
enantiomers. It catalyses the reaction of (S)-α-methylbenzylamine (MBA) and 
pyruvate to acetophenone (AP) and L-alanine (Fig. 1.3). The reaction provides a way 
to quantitatively measure the activity of the enzyme as the equilibrium lies heavily on 
the side of the products [20].  
 
 
Fig. 1.3. Conversion of (S)-α-MBA and pyruvate to acetophenone and L-alanine by omega 
transaminase. The equilibrium of the reaction favours the right hand side [20]. 
 
Generally speaking, omega transaminase enzymes belong to a family of β-
Alanine:pyruvate transaminases where the preferred amino acceptor substrate is 
pyruvate not α-ketoglutarate [20]. The omega transaminase from Pseudomonas 
aeruginosa was revealed to be capable of aminating the aliphatic ketodiol l-
erythrulose [21].  
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In a report by Ward et al 2007 [20], it was shown that the omega transaminase 
obtained from Chromobacterium violaceum did not possess enantioselectivity towards 
either (R)- or (S)-1,3-dihydroxy-1-phenylpropan-2-one as substrates but was highly 
(S)-stereoselectivity in the conversion to 2-amino-1-phenyl-1,3-propanediol with 99 
% of the resulting mixture in the (S) form [22]. This allows a chiral product to be 
made from a non-chiral mixture which is far more cost effective. 
 
C. violaceum omega transaminase was shown to possess high activity towards 
aromatic (S)-amines with the best donors of those tested, 1-aminoindane, 1-methyl-3-
phenylpropylamine and benzylamine. Currently there appears to be no activity 
towards aminodiols by this enzyme. A difference is observed in the initial rates of 
reaction with the (S)-enantiomers of MBA and 1-aminoindane when compared to the 
racemic mixtures of these substrates [20]. This differs to V. fluvialis omega 
transaminase where a racemic mixture resulted in a lower activity, thought to be the 
result of inhibition by (R)-enantiomers [23]. As for acceptors, aliphatic and aromatic 
aldehydes both show good activities for C. violaceum omega transaminase with keto 
acids being the one group that was shown to have low activity. Both V. fluvialis and 
C. violaceum omega transaminases can only utilise L-alanine as an amine donor out 
of the range of α-amino acids tested. Overall it has been shown that C. violaceum 
omega transaminase has a broad substrate range, especially where amine acceptors are 
concerned [20].  
 
1.6. Omega Transaminase Structure 
The crystal structure of C. violaceum omega transaminase was solved by Dr 
Christopher Sayer (Fig 1.4.) [24]. In general transaminases form homodimers with an 
active site consisting of two binding pockets. Each of these subunits consists of a 
large domain where the PLP is bound, made up of a pair of α helices on either side of 
a seven stranded β sheet and a small C-terminal domain. This has a small β sheet with 
α helices around it. There are several essential amino acid residues in the active site 
that are responsible for vital interactions (Fig. 1.5.). An aspartic acid at position 259 is 
needed to form a hydrogen bond with the PLP, the active site lysine that interacts with 
the PLP as described earlier is at position 288 and an arginine which forms a salt-
bridge with α-carboxylate of the substrate is located at position 416 (all numbers refer 
to C. violaceum CV2025 sequence) [20]. In the large substrate binding site of the 
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omega transaminase from V. fluvialis is a pair of tryptophan residues, W57 and W147, 
that control substrate specificity by restricting the active site due to their large side 
chains (Fig. 1.6.). Mutation of these to glycine residues results in increasing the range 
of substrates they accept, allowing them to catalyse the transamination of aliphatic 
amines without losing the original activity of the enzyme towards aromatic amines 
and its enantioselectivity. This suggests that loss of these residues allows increased 
flexibility in the large substrate binding site. Also in the ornithine transaminase 
complexed with an inhibitor, it has been shown that the glutamic acid E235 can mask 
the conserved tyrosine residue, needed to bind the substrates α-carboxylate, via 
hydrogen bonding and salt bridges [25].  
 
Fig. 1.4. Tertiary structure of the holoenzyme of C. violaceum omega transaminase dimer 
viewed normal to the molecular two-fold axis, produced by PyMOL [26] (PDB code 4AH3). 
PLP cofactor is represented by spheres and lighter shaded domains are the small domains 
[24]. 
 
 
PLP in binding 
pocket of large 
domain 
: pair of Large domain
α helices on either 
side of a seven 
stranded β sheet 
terminal -Small C
: small β domain
sheet with α 
helices around it 
Dimer 
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Fig. 1.5. Key residues are shown here represented as stick models using PyMOL [26]. Dashed 
line between Asp259 and PLP represents the hydrogen bond (distance 2.94 Å). PLP is bound 
to Lys288. Right is Arg416. 
 
 
Fig. 1.6. Trp57 and Trp157 are shown here with PLP located between them using PyMOL 
[26]. Large side chains restrict the active site. 
 
1.7. Inhibition of Omega Transaminases 
Both α and ω transaminases are vulnerable to the suicide inhibitor gabaculine (Fig. 
1.7.). This compound acts as a neurotoxin in the body, capable of crossing the blood-
brain barrier and inhibiting GABA-AT and allowing GABA, an inhibitory 
neurotransmitter, to rise significantly [27]. After binding to the active site a Schiff 
base is formed with the PLP and a proton is removed from the β-carbon bound to the 
Asp259 
PLP 
Arg416 
Trp57 
PLP 
Trp157 
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imino group as would happen with a normal amino donor substrate. However with 
gabaculine a second proton is taken from the β-carbon, this creates an unstable 
intermediate that then goes on to form m-carboxyphenylpyridoxamine phosphate 
(mCPP), this is very stable and as such is irreversible preventing PLP from being 
formed again [28][29]. The mechanism is displayed in Fig. 1.8.  
 
 
Fig. 1.7. Molecular structure of the inhibitor gabaculine [30]. 
 
Fig. 1.8. Mechanism of inhibition of transaminase cofactor PLP by gabaculine modified from 
Fu and Silverman, 1999 [30]. 
 
m-carboxyphenylpyridoxamine 
Second proton 
lost from β-
carbon 
Schiff base 
formed with PLP 
Unstable 
intermediate 
First proton  
removed from 
β-carbon 
 17 
 
Fig. 1.9. Gabaculine bound to PLP to form mCPP [24] within the active site drawn using 
PyMOL [26]. 
 
1.8. Differential Scanning Fluorometry Theory 
Protein crystallisation results can sometimes be dependant upon the stability of a 
protein. Disordered proteins crystals can be caused by loose floppy domains which 
prevent proteins packing into ordered crystals. A way around this is to attempt to 
optimise the conditions where the protein is most stable and hence reduce the number 
of different conformations the protein is present in. To achieve this Gibbs free energy 
of unfolding (Gu) must be taken into consideration. This is determined enthalpy (H) 
and entropy (S): G = H – TS. This means that as temperature increases and the protein 
begins to unfold and gain entropy, Gu begins to decrease. At Gu = 0, an equilibrium is 
reached, this is called the Tm where half of the protein is in the folded state and the 
other half in the unfolded state. Therefore a higher Tm value is indicative of a more 
stable protein [31].  
 
Differential scanning fluorometry (thermal shift assay) allows the determination of a 
more thermodynamically stable protein. A number of factors such as buffers, salts, 
pHs' and ligands can be altered and their effects upon the stability of the protein 
measured. Sypro orange is used as a indicator of denatured proteins as it bind to 
hydrophobic regions, which under normal circumstances in cytosolic proteins are 
buried until exposed due to unfolding of the protein. Upon binding there is an increase 
in fluorescence at a wavelength of 610 nm with an excitation wavelength at 492 nm, 
mCPP 
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which can be measured on a quantitative PCR machine [31]. Figure.1.10. shows how 
this works [32]. This allows rapid screening of different conditions in which to 
stabilise the proteins or the stabilisation effect of various compounds when they bind 
to the protein. This technique can sometimes prove invaluable when disordered 
protein crystals are a common result of crystallisation trials. 
 
Figure. 1.10. Visualisation of the correlation between protein unfolding and binding of Sypro 
orange. Y axis displays fluorescence of Sypro orange, X axis displays temperature. Image N 
shows protein in its natural state with hydrophobic regions displayed as grey areas buried. As 
the temperature increases the protein begin to unfold as is shown by image U, Sypro orange 
binds to the hydrophobic regions and fluoresces(orange lines). Figure A shows the denatured 
proteins aggregating together and the amount of available hydrophobic sites for Sypro orange 
binding decreasing. Tm is shown on the image as being halfway between the natural and 
denatured states which corresponds to halfway between baseline and the peak of the curve. 
Figure taken from Niesen et al 2007 [32]. 
 
1.9. Previous Work Relevent To This Project 
1.9.1. Structural Studies of Native Omega Transaminases 
The crystal structure of P. aeruginosa omega transaminase (Fig. 1.11.) has been 
previously solved [24]. Only the holoenzyme of this was resolved, no structure has 
been obtained in complex with substrate or gabaculine bound in the active site.  
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Fig 1.11. Tertiary structure of the holoenzyme of P. aeruginosa omega transaminase dimer 
viewed normal to the molecular two-fold axis, produced by PyMOL [26]. Black sticks 
represent PLP and lighter coloured domains are the small domains [24]. 
 
1.9.2. Site Directed Mutagenesis of Omega Transaminases 
A mutant of C. violaceum omega transaminase was previously made (work to be 
published) with a F89A89 substitution. This was done as part of a group of mutants 
that were produced through site directed mutagenesis to analyse the effects they had 
on the activity of the enzyme towards β-alanine to which the native enzyme has no 
activity towards. The structure of P. aeruginosa omega transaminase which uses β-
alanine as a substrate [21] was analysed and compared to the C. violaceum omega 
transaminase to determine differences that might cause this difference in substrate 
specificity. Substrates such as β-alanine are restricted by their carboxyl group. Arg416 
is responsible for binding the carboxyl group of substrates, whose movement is 
limited by Phe89 in the nearby subunit. After the Arg416 binds β-alanine, the Phe89 
prevents the Arg416 assuming an orientation where the nitrogen group of β-alanine is 
in the catalytic position (Fig. 1.12.). The Phe89 was mutated into an Ala89 in the hope 
that the loss of the aromatic group will result in a more flexible active site which will 
allow β-alanine to be used as a substrate.  
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Fig. 1.12. The Phe89 residue is shown positioned near to Arg416 in the C. violaceum omega 
transaminase [24] (PDB code 4AH3), possibly preventing it from moving into the catalytic 
orientation after binding β-alanine. Image made using PyMOL [26]. 
 
Aims of Project 
The main objective of this project was the purification of Streptomyces avermitilis, 
Pseudomonas putida and Deinococcus geothermalis omega transaminase enzymes and 
to determine their structures through crystallographic methods. None of these omega 
transaminases currently has a crystal structure determined to date. Previous work done 
on the S. avermitilis omega transaminase enzyme has resulted in successful protein 
crystals however none have produced viable data as all have been disordered.  
  
An aim was to also co-crystallize P. aeruginosa omega transaminase in complex with 
the inhibitor gabaculine and in complex with the substrate pyruvate.  
 
Cloned omega transaminase enzymes will be over-expressed and purified using 
Nickel affinity and gel filtration chromatography where possible. Crystallisation trials 
with purified enzyme will be carried out. Crystals of sufficient quality will be 
cryogenically preserved for X-ray diffraction experiments at the Diamond 
Synchrotron.  
 
The C. violaceum omega transaminase should prove capable as a model for the 
structural determination and molecular modelling of the S. avermitilis omega 
transaminase for it has better sequence identity to the S. avermitilis and P. aeruginosa 
Arg416 
Phe89 
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omega transaminase's than they do for one another. The sequence identity between C. 
violaceum and S. avermitilis omega transaminases is 30 %, C. violaceum and P. 
aeruginosa omega transaminases 33 % while S. avermitilis and P. aeruginosa omega 
transaminase only have 23 % sequence identity (Fig. 1.12.)  
 
The F89A mutant C. violaceum omega transaminase enzyme which had previously 
been crystallised by Julia Klose and a data set collected, will be refined in order to 
compare the structure with the wild type enzyme. Assays will be performed to 
determine whether mutating this residue allows the enzyme to use β-alanine. 
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Chapter 2 - Materials and Methods 
All chemicals were obtained from Sigma-Aldrich unless specified otherwise. Where 
appropriate all microbiological equipment was sterilised before use by autoclaving at 
121
o
C for 20 minutes. Solvents were all analytical grade and those used in HPLC 
assays were HPLC grade. Double distilled purite water (ddH2O) was used wherever 
water was a necessary solvent unless specified otherwise.  
 
2.1. Enzyme Purification 
2.1.1. Buffers 
Buffer A: Primary buffer 
50 mM Tris-HCl pH 7.5/ 8.0/ 6.3 
50 μM PLP  
 
Buffer B: Nickel column buffer 
50 mM Tris-HCl pH 7.5 
1 M Imidazole  
50 μM PLP 
 
Buffer C: Gel filtration buffer 
50 mM Tris-HCl pH 7.5 
100 mM NaCl 
50 μM PLP 
 
Buffer D: Hydrophobic interaction chromatography buffer 
50 mM Tris-HCl pH 7.0 
1 M Ammonium sulphate 
50 μM PLP  
 
Buffer E: Ion exchange buffer 
50 mM Tris-HCl pH 7.5/ 8.0/ 6.3 
1 M NaCl 
50 μM PLP  
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2.1.2. Bacteria Cultures and Storage 
The cloned omega transaminase enzymes were provided by John Ward, UCL. 
Escherichia coli BL21 Star
TM
 (DE3) pLysS cells were used containing the pET29a 
vector (Novagen, Nottingham UK) that possessed either the S. avermitilis, P. putida 
or D. geothermalis omega transaminase genes. The other species was E. coli BL21 
Gold containing the vector pET-24a(+) (Novagen, Nottingham UK) that had the P. 
aeruginosa omega transaminase gene within it. All genes were His-tagged and the 
vector carried a gene for kanamycin resistance to allow selection of cells containing 
the vector. A T7 promoter lies upstream of the omega transaminase gene which 
requires the T7 polymerase whose expression is under the control of a lac operator 
that is repressed in the absence of lactose. The expression of the T7 polymerase and 
the omega transaminase gene is induced by addition of IPTG which is an analogue of 
lactose [33]. 
  
Glycerol stocks were made by mixing 50 μl of 50 % sterile glycerol (Fisher 
Scientific) and the same amount of bacteria culture and flash frozen in liquid nitrogen 
and then stored in a -80
o
C freezer. 100 μl of glycerol stock was added to 100 ml of 
lysogeny broth (LB) (25 % w/v) (MELFORD) with 100 μl of 50 mg/ml kanamycin 
under sterile conditions and incubated at 37
o
C at 200 rpm overnight. Then to each 1 
litre flask, 20 ml of the overnight culture was added with 1 ml 50 mg/ml kanamycin 
and these were incubated under the same conditions until an optical density (OD) of 
0.8 at 600 nm was reached at which point 1 ml IPTG (MELFORD) was added and 
then allowed to incubate for a further 4 hours. Cultures were then spun down at 12000 
g for 30 min to obtain a cell paste. The supernatant was discarded and the paste was 
frozen and stored at -20
o
C. Overexpression of the respective omega transaminase was 
checked by running a SDS-PAGE gel and looking for a clear band around 50 kDa 
 
2.1.3. Lysing Cell Cultures 
For each 1 g of cell paste, 10 ml of Buffer A was used to resuspend the pellet. The 
E.coli cell paste over-expressing the S. avermitilis omega transaminase was much 
more viscous and difficult to resuspend so 7 μl bezonase nuclease (≥250 units/μl) was 
added to digest the nucleic acid. Samples were then sonicated ten times for 15 
seconds in ice with 45 seconds between sonications with a Soniprep 150 Sonicator 
 24 
(Sanyo). The suspension was then centrifuged at 12000 g for 20 minutes and the 
supernatant poured off and the pellet disposed of. 
 
2.1.4. SDS-PAGE gels 
SDS-PAGE separates proteins based on their molecular weight. Gels were prepared in 
advance. The apparatus used was a Bio-Rad Mini-protein II vertical electrophoresis 
apparatus (Bio-Rad Laboratories Ltd). Gels were made between two glass plates 1 
mM apart and water was added first to ensure no leaks and the plates dried again 
using filter paper. The separating gel was added until it was 2/3 full and allowed to 
polymerize at room temperature before adding the stacking gel and the comb to form 
the wells. 
 
Separating Gel:  4.2 ml 30 % Acrylamide/bisacrylamide (29:1) 
2.5 ml 1.5 M Tris-HCl, pH 8.6 
1.0 ml 10 % SDS w/v 
2.3 ml ddH2O 
Stacking Gel:     2.0 ml 30 % Acrylamide/bisacrylamide (29:1) 
2.5 ml 0.5 M Tris-HCl, pH 6.8 
1.0 ml 10 % SDS w/v 
4.5 ml ddH2O 
 
10 µl TEMED and 100 µl APS (10 % w/v) were added to each of the gel solutions 
just before they were loaded into the apparatus. APS was made fresh each time and 
butan-2-ol was put on top of the separating gel to remove any bubbles and to stop it 
from drying out until it had polymerized enough for the stacking gel to be added. 
 
10 μl of a sample and 10 μl of the loading buffer (100 mM Tris-HCl, pH 8.0, 2 % β-
mercaptoethanol v/v, 4 % SDS w/v, 0.2 % bromophenol blue w/v, 20 % glycerol v/v) 
were mixed together to denature the protein. The SDS binds to the protein unfolding it 
and adds a negative charge. The mercaptoethanol reduces any disulphide bonds. The 
sample was then put in a Heatblock for 5 minutes at 100
o
C. The samples were then 
added to the wells formed by the comb using a 50 µl Hamilton glass syringe. 5 µl of a 
molecular weight marker (ladder) was added to the first well (Biorad, 10-250 kDa). 
Gels were run for 50 minutes at 200 V in a running buffer containing 25 mM Tris, 
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192 mM glycine and 0.1 % SDS at pH 8.3. Staining was done by microwaving the 
gels in the stain (1 g Coomassie Brilliant Blue, 1 L methanol, 800 ml ddH2O, 200 ml 
glacial acetic acid) for 5 minutes, then 15 minutes in water. An over-expression band 
corresponding to a molecular weight of 50 kDa, using the ladder as a control, verified 
the likelihood of the omega transaminase being present within the sample.  
 
2.1.5. Purification of enzymes 
An automated FPLC (GE Pharmacia AKTA Purifier) was used with the columns 
mentioned below in a cold room at 7
o
C.  
 
2.1.6. Nickel Affinity Chromatography 
A 10 ml Hiload column (Pharmacia) was equilibrated with three column volumes of 
Buffer A pH 7.5 with a flow rate of ≤ 3 ml/min. Samples were applied to the column 
using a 10 ml or 50 ml Superloop and any unbound protein was washed out with three 
column volumes of Buffer A pH 7.5. Bound proteins were eluted with Buffer B up to 
a concentration of 100 %. Columns were washed afterwards with three column 
volumes of ethanol (Fisher Scientific). Absorbance was measured at 280 nm to 
determine which fractions contained the protein of interest which was then confirmed 
by running an SDS-PAGE gel.  
 
2.1.7. Hydrophobic interaction chromatography 
A 20 ml Phenyl Sepharose column (GE Healthcare) was equilibrated with three 
column volumes of Buffer D with a flow rate of ≤ 3 ml/min. Samples in Buffer D 
were applied to the column using a 10 ml or 50 ml Superloop. Two column volumes 
of Buffer D were run through to wash out unbound protein and a linear gradient from 
Buffer D to Buffer A pH 7.5 over three column volumes was applied. Absorbance 
was measured at 280nm to determine which fractions contained proteins which were 
then tested by running an SDS-PAGE gel. 
 
2.1.8. Ion exchange chromatography 
A 12 ml anion exchange column (Fast Flow Q, GE Healthcare) was equilibrated with 
three column volumes of Buffer A at pH 7.5. This was one pH unit above the 
theoretical pI of the protein of interest as determined by ProtParam (Expasy tools, 
http://www.expasy.ch/tools/protparam.html). Samples from the Phenyl Sepharose 
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column dialysed against Buffer A pH 7.5 were loaded onto the column, three column 
volumes the same buffer was used to wash out unbound protein. A gradient from 0-1 
M NaCl Buffer E pH 7.5 over five column volumes was used followed by 10 ml at 
100 % Buffer E. The experiment was repeated at pH 8.0. Both failed to bind the 
protein of interest so the experiment was repeated using a 1 ml cation exchange 
column (Fast Flow S, GE Healthcare) with Buffers A and E at pH 6.3. Samples were 
injected using a 50 ml superloop, washed with 10 ml of Buffer A at pH 6.3 and eluted 
up to 100 % Buffer E pH 6.3 over a 20 ml gradient followed by 5 ml at 100 % Buffer 
E pH 6.3. 
 
2.1.9. Gel Filtration Chromatography 
Samples from the Nickel column were concentrated using a Vivaspin concentrator 
(Vivascience) with a 10 kDa cut-off to ≤ 2 ml. A GF200 column (Superdex 200 
Hiload 16/60, GE Healthcare) was equilibrated with one column volume of Buffer C 
with a flow rate of ≤ 1 ml/min depending on the pressure. Samples were applied using 
a 2 ml injection loop and eluted with one column volume of Buffer C into 1.5 ml 
fractions. Absorbance was measured at 280 nm to determine the fractions that 
contained protein and the protein was determined by SDS-PAGE gels. Fractions with 
omega transaminase were then pooled together. 
 
2.2. Crystallisation Trials 
2.2.1. Protein Concentration Determination 
A NanoDrop 2000c spectrophotometer (Thermo Scientific) was used to determine the 
concentration of protein samples. 2 μl of Buffer C was added as a blank and was 
cleaned off with a medical wipe before adding 2 μl of the protein sample. Each time it 
was ensured that there were no air bubbles in the droplet and the arm was lowered 
down properly before scanning. Samples were scanned at 280 nm and the 
concentration automatically calculated in mg/ml once provided with the extinction 
coefficient, from the ExPASy Proteomics Server by submitting the amino acid 
sequence of the protein in question, and the molecular weight of the protein. The 
sensor was cleaned before and after use with ethanol (Fisher Scientific) and then with 
distilled water using a medical wipe. 
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2.2.2. Crystal Screening 
A concentration of 10 mg/ml is required for crystallisation so samples were spun 
down in a Vivaspin centrifugal concentrator (Vivascience) with a size cut-off at 10 
kDa until the volume as determined by the equation V1 x C1 = V2 x C2 is reached. 
 
An Oryx 6 crystallisation robot (Douglas Research, UK) was used to set up 
microbatch crystallisation trials in a Hampton 96 well plate. The program used 
dispensed a 50:50 mix of protein: precipitation condition into each well to a volume 
of 1 μl and covered each one in Al's oil (50 % silicon oil, 50 % paraffin oil). They 
were then incubated at 19
o
C and monitored under a light microscope for crystal 
growth. The screens used were Sigma 82009 and 70437 (Sigma Aldrich), MDL-01 
and MDL-02, JCSG plus, MIDAS and Morpheus (Molecular Dimensions Limited).  
 
2.2.3. Crystal Soaks 
P. aeruginosa omega transaminase was the subject of these trials. Crystal soaks were 
done with crystals from a range of conditions (Table. 2.1.) which were then soaked 
for 15-30 seconds in an existing cryo-protectant with pyruvate added so it consisted of 
50 μM PLP, 100 mM NaCl, 50 mM Tris, 12 % w/v PEG 3350, 30 % v/v PEG 400 
and 10 mM sodium pyruvate.  
 Salt Buffer pH Precipitant 
Sigma 
70437 
None None - 10 % w/v PEG 1000 10 % w/v PEG 8000 
Sigma 
70437 
0.2 M 
magnesium 
chloride 
0.1 M Bis 
Tris 
5.5 25 % w/v PEG 3350 
JCSG plus None None 6.5 1.6 M tri-sodium citrate 
JCSG plus 
0.04 M 
potassium 
dihydrogen 
phosphate 
None - 16 % w/v PEG 8000/ 20 % v/v Glycerol 
MD1-01 
0.2 M 
magnesium 
chloride 
0.1 M Tris 8.5 30 % w/v PEG 4000 
Table. 2.1. List of conditions where P. aeruginosa omega transaminase crystals were formed 
which were used in crystal soaking experiments. 
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2.2.4. Co-crystallisation 
Separate co-crystallisation trials were set up for P. aeruginosa omega transaminase 
with pyruvate and with gabaculine. Pyruvate co-crystallisation was repeated three 
times, each with a different concentration of sodium pyruvate. The protein 
concentration remained close to 10 mg/ml each time while sodium pyruvate was 
varied to 10 mM, 30 mM or 37.5 mM. Samples were mixed together and incubated at 
room temperature for 30 minutes before being used in crystal trials. 
 
Gabaculine co-crystallisation was done by calculating the concentration of the protein 
in molarity (0.48 mM) and making a solution of gabaculine approximately double that 
of the protein since it is such a potent inhibitor, which in this instance was 1 mM. 
Equal amounts of gabaculine and protein solutions were mixed and incubated at room 
temperature for 30 minutes before being used in crystallisation trials. 
 
2.2.5. Crystal Optimisation 
X-step optimisation software (Douglas Instruments) was used to design crystallisation 
optimisation conditions. Two runs were set up both based on conditions that produced 
the best protein crystals from crystallisation trials. The first had the following 
condition and variables; Protein 3-6 mg/ml, Succinic acid 25-38 mM, PEG3350 5-
13.625 % w/v, pH 5.41-6.14. The second was as follows; Protein 4.125-5 mg/ml, Tris 
3.5-25 mM, PEG 8000 1.5-8.5 % w/v, pH 7.0-7.43.  
 
2.2.6. Freezing Crystals 
Crystal growth was monitored over a period of days or weeks and any crystals that 
were considered good enough to be used were frozen for future use. Crystals were 
mounted on nylon loops in the droplet under a microscope. Liquid nitrogen was used 
as the freezing agent and was also used to store the crystals in. Crystals were 
submerged for a few seconds in a cryo-protectant to prevent intrinsic ice formation 
which could damage the crystal or interfere with the X-ray diffraction patterns, where 
necessary. Cryo-protectants were initially individually tailored to the conditions of the 
well the crystals were grown in as well as the conditions they were eluted in during 
gel filtration. Where the precipitation conditions were similar in terms of the 
molecular weight of the PEG used, the cryo-protectants that were made earlier were 
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used again for these. Table. 2.2. shows the list of cryo-protectants that were made, 50 
μM PLP was included in each. 
 
Crystals obtained from the Morpheus screen were already cryo-protected and as such 
were frozen straight from the droplet. The same was done for conditions from other 
screens where the precipitant used was at a high enough concentration to act as a 
cryo-protectant itself.  
 
pH Salt Buffer Protectant 1 Protectant 2 
7.0 - 
50 mM 
Tris 
12 % w/v 
PEG 3350 
30 % v/v PEG 400 
7.0 0.1 M NaCl MgCl2 
8 % w/v 
PEG 8000 
30 % v/v PEG 400 
8.5 0.2 M MgCl2 
0.1 M 
Tris 
22 % w/v 
PEG 4000 
25 % v/v PEG 400 
8.5 
0.2 M 
trisodium 
citrate 
0.1 M 
Tris 
- 30 % v/v MPD 
Table. 2.2. List of cryo-protectants made.  
 
2.3. Assays 
2.3.1. HPLC Assay 
Two assays were carried out. The control assay to ensure enzymatic activity had not 
been lost contained the following; 25 mM MBA, 10 mM pyruvate, 100 mM HEPES 
pH 8.0 and 0.5 mM PLP. 0.5 mg of omega transaminase enzyme was added to the 
stock assay up to a total volume of 1 ml. The assay to detect β-alanine activity 
contained the following; 25 mM β-alanine , 10 mM acetophenone, 100 mM HEPES 
and 0.5 mM PLP. 0.5 mg of omega transaminase was added to a total volume of 1 ml 
as before and a repeat at a concentration of 2 mg of enzyme was also made. A crude 
lysate of the wild type C. violaceum omega transaminase was used as a control as a 
purified sample was not available at the time. Samples were shaken in an incubator at 
800rpm and tested over time. 100 μl of the incubated samples was mixed with 100 μl 
acetonitrile, vortexed and then centrifuged at 13000 g for 1 minute. The supernatants 
were then transferred into HPLC vials with glass inserts in them so the sampler could 
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reach them. The absorbance was then measured at 250 nm over time for acetophenone 
production in an HPLC (Varian ProStar) [34].  
 
The HPLC running program was as follows; 60 % H2O and 40 % acetonitrile for 5 
minutes. Then to 20 % H2O and 80 % acetonitrile over 5 minutes and lasting for 30 
seconds. 2 % H2O and 98 % acetonitrile over 2 minutes lasting for 30 seconds before 
returning to 60 % H2O and 40 % acetonitrile over 5 minutes.  
 
Samples of purified F89A mutant omega transaminase were stored in a -80
o
C freezer 
prior to assays.  
 
2.3.2. Tetrazolium Salt Based High-Throughput Assay  
Colourimetric assays were carried out using 100 mM HEPES pH 8.0, 10 mM β-
alanine, 20 mM pyruvate, 5 μg/ml 1-Methoxy-5-Methylphenazinium Methyl Sulphate 
(mPMS), 40 μg/ml PLP, 0.2 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), 0.5 mM NAD
+ 
and 1.5 mg/3 mg of omega 
transaminase and alanine dehydrogenase whose amount has to be determined. The 
formation of the reduced form of the trizolium salt MTT, which possesses a dark blue 
colouration, was measured with mPMS used as a hydrogen carrier between NADH 
and MTT. Samples were analysed in a SpectraMax plate reader (Molecular Devices) 
and colour change monitored by detecting absorbance at 405 nm.  
 
2.3.3. Amino Acid Oxidase/Horseradish Peroxidase Linked Assay 
A stock assay was made to 10 ml containing 15 mM β-alanine, 0.2 mg/ml pyruvate, 
100 mM HEPES pH 8.0, 4 mg/ml 2, 4, 6-tribromo-3-benzoic acid (TBHBA), 3 mg/ml 
4-aminoantipyrine (4-AAP), 50 μM PLP, 1 mg horseradish peroxidase and 8 units of 
L-amino acid oxidase. To 50 μl of enzyme 100 μl of stock assay was added in a 96 
well microtiter plate (Greiner Bio-one) to a final enzyme concentration of 1 mg/ml. 
Positive and negative controls were made with 50 μl Buffer A and 50 μl 60 mM (final 
concentration 20 mM) DL-alanine. Absorbance was measured at 510 nm in a 
microplate reader (Tecan) [35]. 
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2.3.4. Differential Scanning Fluorometry 
A purified protein sample was diluted to 2.5 μM concentration and to a volume of 4.2 
ml with Buffer A pH 7.5. To this 4.2 μl of 5000 x Sypro Orange was added. 16 μl 
samples were mixed with 24 μl of buffer listed in Table. 2.3. within a 96 well white 
quantitative PCR plate (Fisher Scientific) on ice with each condition repeated three 
times each for reliability. The plate was then sealed with optical sealing tape (Bio-
Rad), gently shaken and then spun down in a centrifuge at 300 g for two minutes. 
Samples where then placed within a quantitative PCR machine (Stratagene Mx3005P) 
and heated to 25
o
C for 5 minutes. The temperature was then increased by 1
o
C each 
minute with a reading taken for every degree Celsius change in temperature. Data was 
then exported to Excel and analysed using Graphpad Prism to calculate the Tm values 
by using the Boltzmann equation (Fig. 2.1.) [31][32].  
 
 
Fig. 2.1. Boltzmann equation. 
 
Buffer pH 
Tris 7 7.5 8     
Bis-Tris 6 6.5 7     
Bis-Tris Propane 6.5 7 7.5 8   
Bicine 7.6 8       
EPPS 7.5 8       
HEPES 7 7.5 8     
PIPES 6.6 7 7.5     
MOPS 6.5 7 7.5     
MES 6 6.5       
Trisodium citrate 6         
Potassium acetate 5.8         
Potassium phosphate 6 6.5 7 7.5 8 
Table. 2.3. List of buffers and the range of pH's used in the Differential Scanning Fluorometry 
experiment.  
 
 
I = A + 
B - A 
1 + e(Tm – T)/ C 
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2.4. Bioinformatics 
2.4.1. Multiple Sequence Alignment 
ClustalW from EBI Database was used to perform a multiple sequence alignment 
between C. violaceum (CV2025), P. aeruginosa (PA0132), S. avermitilis (SAV4551), 
P. putida (KT2440) and D. geothermalis (DSM11300) omega transaminases. 
 
2.4.2. Homology Modelling 
The software 'MOE' [36] was used to create a model of S. avermitilis omega 
transaminase based on the structure of the C. violaceum holoenzyme solved by Dr 
Christopher Sayer [24]. The 30 % sequence homology and the fact that it is part of the 
same sub-class of enzymes makes it a good template to base the structure on.  
 
The known sequence for S. avermitilis omega transaminase was used as well as the 
PDB file for the structure of the C. violaceum holoenzyme. The sequences of the two 
were aligned and then superimposed to align them taking into account the predicted 
secondary structure. Amber 99 with a reaction field treatment of solvation 
electrostatics for force field predictions was used to create and destroy hydrogens and 
lone pairs as appropriate to assign partial charges and complete the outer valence 
electron shells.  
 
2.4.3. X-ray Data Collection 
Data was collected using the Diamond Synchrotron Light Source on beamline I03 by 
Dr Christopher Sayer with myself present. Crystals were kept in cryo-conditions 
within a stream of liquid nitrogen. Data was processed by the programs Xia2 [37] and 
MOSFLM [38]. Molecular replacement was performed by MOLREP [39]. 
 
2.4.4. Structural Refinement 
The program COOT [40] was used to perform structural refinement between the 
structure and the electron density map, alterations were made manually based on both 
of the Fourier transformations 2Fo-Fc and Fo-Fc. Additionally it was used for the 
addition of water molecules to the model. REFMAC [41] was used between rounds of 
manual refinement with COOT to reduce the R factor and free R factor. 
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Chapter 3 - Results 
3.1. Protein Purification 
3.1.1. Successful Purification Experiments 
SDS-PAGE gels were run after sonication to confirm the presence of the over- 
expressed omega transaminase enzyme. Strong bands within the appropriate size 
range were seen in all of the cloned omega transaminase enzymes from different 
species.  
 
Purification of the cloned omega transaminases began with Nickel chromatography in 
an attempt to isolate the His tagged protein. SDS-PAGE were run to see if this was 
successful and as Fig. 3.1. and 3.4. show there were clear bands in wells three to five 
and three to six respectively that were approximately 50 kDa in size from one of the 
peaks. The second well contained a sample from the flow-through and showed that 
most of the other proteins were eluted in that one. However there were more bands in 
the other wells which means other proteins were still contaminating the sample. A 
second round of purification was performed by using gel filtration chromatography, 
traces are shown in Fig. 3.2. and Fig. 3.5. A clear and decisive peak was seen for each 
giving the probable location of the omega transaminase, which was confirmed by 
running further SDS-PAGE gels. Fig. 3.3. shows the results of gel filtration for the P. 
aeruginosa omega transaminase, 50 kDa bands were seen in wells three and four 
which were taken from either end of the large peak. The other wells contained sample 
from minor peaks seen in the trace, no other proteins were seen this time with the 
omega transaminase. The same was seen in Fig. 3.6. for S. avermitilis omega 
transaminase purification where the fifth well showed a significant amount of a 
second, smaller protein while the second, third and fourth wells possessed only a band 
around 50 kDa. Fig. 3.7. shows the results after gel filtration for P. putida omega 
transaminase where there was clear indication of successful purification as well. 
 
Wild type C. violaceum omega transaminase was also purified to act as a control in 
the amino acid oxidase/horseradish peroxidise linked assay. The protocol for 
purification produced a pure sample after Nickel and gel filtration chromatographies 
as shown on the SDS-PAGE gel in Fig. 3.8. 
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Fig. 3.1. SDS-PAGE for P. aeruginosa omega transaminase after Nickel affinity 
chromatography with marker in well 1. Wells 3-5 indicating presence of omega transaminase, 
well 2 taken from flow-through. 
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Fig. 3.2. Trace from gel filtration chromatography for P. aeruginosa omega transaminase 
with green line indicating location of protein elution. Major peak seen between 60 and 70 ml. 
Minor peaks at 20 ml and 105 ml. 
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Fig. 3.3. SDS-PAGE for P. aeruginosa omega transaminase after gel filtration 
chromatography. First well contained ladder, third and fourth wells show 50 kDa bands, other 
wells were taken from other peaks and show no other bands to those seen in the third and 
fourth. 
 
 
 
Fig. 3.4. SDS-PAGE for S. avermitilis omega transaminase after Nickel affinity 
chromatography with marker in well 1. Wells 3-6 indicating presence of omega transaminase 
were contaminated with other proteins as can be seen from other bands, well 2 taken from the 
peak before imidazole was added.  
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Fig. 3.5. Trace from gel filtration chromatography for S. avermitilis omega transaminase with 
green line indicating location of protein elution. Major peak seen between 60 and 70 ml, 
minor peaks at 30 ml, 73 ml and 89 ml.  
 
 
 
Fig. 3.6. SDS-PAGE for S. avermitilis omega transaminase after gel filtration 
chromatography. First well contained ladder, second, third and fourth wells show 50 kDa 
bands, other wells were taken from other peaks and show no bands similar  to those seen in 
the third and fourth. 
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Fig. 3.7. SDS-PAGE for P. putida omega transaminase 
after gel filtration chromatography. First well contained 
ladder, the fifth, sixth, seventh, eighth and ninth wells 
show 50 kDa bands. Other wells were taken from other 
peaks and show no bands similar to those seen in the 
ones mentioned. 
 
 
 
 
 
 
Fig. 3.8. SDS-PAGE for C. violaceum omega transaminase after gel filtration 
chromatography. First well contained ladder, the second, fifth, sixth and seventh wells 
contained small peaks on the trace. The third and fourth wells were from the main peak and 
contained 50 kDa bands. 
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3.1.2. Attempts at the Purification of D. geothermalis omega transaminase 
The D. geothermalis omega transaminase required a more inventive approach to 
purify it as it failed to bind to the Nickel column despite being His-tagged. 
Hydrophobic interaction chromatography was used as an initial step to separate 
proteins based on their hydrophobic properties. Fig. 3.9. shows the trace from this 
column with two clear peaks as the concentration of ammonium sulphate decreased 
resulting in a less charged environment allowing elution of the protein which was 
confirmed by SDS-PAGE (Fig. 3.10.). The protein of interest was eluted in the second 
peak.  
 
The next step was to perform ion exchange chromatography to separate proteins based 
on their ionic properties. A pH of 7.5 was initially used as it was close to 1 pH unit 
above the theoretical pI of the protein which was determined as 5.96 by ProtParam. 
Fig. 3.11. shows the trace from this and with the two peaks near the end of the 
gradient it was expected that one of these would contain the protein of interest. 
However after SDS-PAGE (Fig. 3.12.) it was shown that the protein had been eluted 
in the flow-through so the experiment was set up again with the buffers at a pH of 8 in 
case the estimated pI was too low. Again the same results were seen so a cation 
exchange column was set up and the pH of the buffer altered to 6.3 assuming the 
estimated pI was completely wrong. Again the protein of interest was eluted in the 
flow-through. However the protein that eluted in the flow-through of the FFQ column 
at pH 7.5 was relatively pure (Fig. 3.11.). 
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Fig. 3.9. Trace from hydrophobic interaction chromatography for D. geothermalis omega 
transaminase with green line indicating location of protein elution. The concentration of 
buffer D represented as the red trace. 2 peaks are seen as the concentration of buffer D 
decreases and the environment becomes less charged. 
 
 
Fig. 3.10. SDS-PAGE for D. geothermalis omega transaminase 
after hydrophobic interaction chromatography. The first well 
contained the ladder, the second, third and fourth wells 
contained the flow-through. The fifth, sixth, seventh, eighth 
and ninth wells contained the first peak and the tenth well 
contained the second peak. Protein is 42 kDa so was located 
just below the 55 kDa marker in the tenth well as indicated by 
the arrow. 
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Fig. 3.11. Trace from ion exchange chromatography for D. geothermalis omega transaminase 
with green line indicating location of protein elution. The concentration of buffer E 
represented as the red trace. Two peaks are seen as the concentration of NaCl increased.  
 
 
Fig. 3.12. SDS-PAGE for D. geothermalis omega transaminase 
after ion exchange chromatography using an anion exchange 
column. The first well contained the ladder, the second well 
contained a sample just before the flow-through, the third and 
fourth wells contained the flow-through, the fifth, sixth, seventh 
and eighth wells contained samples between the flow-through and 
the first peak. The eighth contained the first peak, the ninth the 
second peak and the tenth contained the end of the graph after the 
second peak. The protein is 42 kDa so was located close to the 40 
kDa marker. 
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3.2. Protein Crystallisation and Structural Determination 
All crystallisation trials were carried out by myself. The X-ray data collection and 
data analysis was carried out with Dr Michail Isupov. The refinement of the data from 
the C. violaceum F89A omega transaminase mutant was carried out by myself. 
 
3.2.1. Crystallisation Trials 
P. aeruginosa omega transaminase proved to be the easiest to crystallise with many 
protein crystals clearly visible in a variety of wells in each of the three screens used at 
the time; MDL, Sigma and JCSG plus. The most highly ordered crystals appeared to 
be very thin yet large, plate-like crystals (Fig. 3.13.). These were quite common and 
while fragile, proved to be capable of providing high resolution data of the 
holoenzyme at the Diamond Synchrotron. The data was collected at 1.7 Å resolution 
and was processed easily. This gave a good indication that this type of crystals which 
were seen later on, are possible of providing good data to work with.  
 
While not as numerous as observed for the P. aeruginosa omega transaminase,          
S. avermitilis omega transaminase provided some crystals for testing. The best two 
conditions where there were a good number of good sized, disc-like crystals formed 
(Fig. 3.14.). The rest were mainly clusters of crystals which could not be separated. 
Both of these were from the JCSG-plus screen and are listed below, each had a cryo-
protectant specifically designed for it; 
B8: (0.2 M, MgCl2, 0.1 M Tris, pH 7, 10 % w/v PEG 8000)   
G7: (0.1 M succinic acid, pH 7, 15 % w/v PEG 3350).  
While under the microscope these looked to be good, when tested with X-ray 
diffraction they were very disordered. The conditions for crystallisation have been 
optimised.   
 
The crystals from B8 were put onto a loop and momentarily suspended in a cryo-
protectant made of 50 μM PLP, 100 mM NaCl, 200 mM MgCl2, 8 % PEG 8000 and 
30 % PEG 400, before being placed into a tube in liquid nitrogen. The same 
procedure was carried out with G7 with a different cryo-protectant of 50 μM PLP, 
100 mM NaCl, 50 mM Tris, 12 % PEG 3350 and 30 % PEG 400.  
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2.5mm 
 
 
Fig. 3.13. P. aeruginosa omega transaminase protein crystals. The picture shows numerous 
plate-like crystals stacked on top of one another. The yellow colouration indicates presence of 
the PLP coenzyme which is yellow in its natural state. Crystallisation conditions used were 
0.2 M magnesium chloride, 0.1 M Tris, 30 % w/v PEG 4000 at pH 8.5.  
 
 
 
 
Fig. 3.14. JCSG plus crystal dish containing S. avermitilis omega transaminase protein 
crystals. Protein seems to form numerous small, disc shaped crystals. The yellow colouration 
indicates the presence of the PLP coenzyme which is yellow in its natural state. Conditions 
were 0.2 M MgCl2, 0.1 M Tris, 10 % w/v PEG 8000 at pH 7.0. The largest and most ordered 
crystals were cryogenically frozen for future use. 
 
 
 
 
2.5mm 
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3.2.2. Crystal Soaks 
Two of the P. aeruginosa omega transaminase crystals that were taken to the 
Synchrotron produced good data to a resolution of 2 Å, their growth conditions were 
0.04 M potassium dihydrogen phosphate, 16 % w/v PEG 8000 and 20 % v/v Glycerol 
for the first. The second was 0.2 M magnesium chloride, 0.1 M Tris, 30 % w/v PEG 
4000 at pH 8.5. There were problems concerning the space group of the second 
dataset which prevented molecular replacement. The first underwent molecular 
replacement successfully using MOLREP [39], when refined using REFMAC [41] an 
R factor of 0.187 and a free R factor of 0.242 was obtained. It was clearly apparent on 
inspection that there was nothing in the active site so no further work was done with 
it.  
Space group                     P212121 
Unit cell parameters                109.65 Å   111.49 Å   135.03 Å    90
o
   90
o
   90
o
 
 
Resolution                                 Overall     Low      High 
Low resolution (Å)                     50.80     50.80     2.08 
High resolution (Å)                     2.03       9.08       2.03 
Rmerge                                        0.090     0.040     0.642  
I/sigma                                         9.9         21.6       2.7 
Completeness (%)                       99.5       98.1       99.9 
Multiplicity                                  5.3         4.9         5.5 
 
Fig. 3.15. Statistics from X-ray data collected at the Diamond Synchrotron for the                   
P. aeruginosa omega transaminase and pyruvate crystal soak whose growth conditions were 
0.04 M potassium dihydrogen phosphate, 16 % w/v PEG 8000 and 20 % v/v Glycerol.  
 
3.2.3. Co-crystallisation trials 
Purified P. aeruginosa omega transaminase was concentrated to higher concentrations 
to compensate for the dilution involved.  Initially gabaculine was added to a final 
concentration of 20 mM as was previously described [24]. However for this protein 
there was an obvious and immediate denaturation upon adding the gabaculine. Since 
it was such a potent inhibitor the concentration was reduced to approximately double 
that of the protein to a concentration of 1 mM which prevented this from happening. 
Five different screens were set up, of these MDL and Sigma did not provide any 
viable crystals. The screens and conditions that provided crystals that were good 
enough to freeze for future data collection are listed below in Table. 3.1. Only four of 
the crystals were scanned due to limited time during the last Synchrotron trip. Three 
of these were from a single well, its conditions were 60 mM MgCl2; CaCl2, 0.1 M 
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Tris; Bicine, 30 % PEGMME 550; PEG 20000 at pH 8.5. None of the crystals from 
this well produced good diffraction. The fourth well did provide data that could be 
used. Its conditions were 90 mM NaF; NaBr; NaI, 0.1 M Tris; Bicine, 30 % 
PEGMME 550; PEG 20000 at pH 6.5 and is shown in Fig. 3.16. Data was collected to 
2.2 Å resolution and had a space group C222 however it was marred by ice rings and 
the data collected was very weak and could not be processed (Fig. 3.19.). 
 
  Salt Buffer pH Precipitant 
Morpheus 60 mM MgCl2; 
CaCl2  
Tris; Bicine 
0.1 M  
8.5 30 % PEGMME 
550; PEG 20000 
  90 mM NaF; 
NaBr; NaI 
Tris; Bicine 
0.1 M  
6.5 30 % PEGMME 
550; PEG 20000 
  90 mM NaN03; 
Na2HPO4; 
(NH4)2SO4 
Tris; Bicine 
0.1 M  
6.5 30 % PEGMME 
550; PEG 20000 
MIDAS  10 % v/v 
ethanol 
0.1 M MES-
NaOH 
6.0 30 % w/v 
polyacrylate 5100 
sodium salt 
JCSG plus 0.2 M LiSO4  0.1 M sodium 
acetate 
4.5 50 % v/v PEG 
400 
  None None 6.5 1.6 M tri-sodium 
citrate 
  0.2 M LiSO4 0.1 M sodium 
acetate 
  30 % w/v PEG 
8000 
  None 0.1 M Tris 8.0 20 % v/v MPD 
  None 0.1 M Na 
Citrate 
5.0 3.2 M ammonium 
sulphate 
Table 3.1. List of screens which produced crystals that were frozen from P. aeruginosa co-
crystallisation experiments with gabaculine. 
 
P. aeruginosa omega transaminase was co-crystallised with pyruvate and screens 
were made with the three different concentrations at 10 mM, 30 mM and 37.5 mM 
sodium pyruvate after incubation. The screens and conditions that provided crystals 
that were good enough to freeze down are listed below in Table. 3.2. Only one was 
scanned due to the limited time during the last Synchrotron trip. Its conditions were 
0.1 M sodium citrate, 20 % w/v PEG 3000 at pH 5.5. Data was collected to 1.8 Å 
resolution and was assigned the same space grouping as the gabaculine co-
crystallisation with a space grouping P212121 with four subunits (Fig. 3.21.).  
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The data were successfully processed by Xia2 3dr [37] during data collection, 
however there were issues when it came to molecular replacement with MOLREP 
[39] as after refinement, converged with a free R of 0.41. There were breaks in the 
main chain electron density that indicated that the space group assignment might be 
incorrect. There were only two strong rotational peaks suggesting two subunits in the 
asymmetric unit, or possibly four subunits with similar orientation. Molecular 
replacement using MOLREP checked all possible space groups and suggested the best 
solution was a P212 2 with a correlation of 0.33. However this solution had only two 
monomers per asymmetric unit and could not be refined to a free R better than 0.47. 
In the end the data was submitted to York Structural Biology Laboratory program 
server to run Zanuda [42] which assigned the correct space grouping of P21212 where 
the solution could be refined to a free R below 0.25. Upon examination of the active 
site it was clear that there was no pyruvate within it. (Work done under Dr Michail 
Isupov). 
 
  Salt Buffer pH Precipitant 
JCSG 0.2 M NaCl 0.1 M 
sodium 
cacodylate 
6.5 2.0 M 
ammonium 
sulphate 
  0.2 M 
ammonium 
chloride 
None     - 20 % w/v PEG 
3350 
  None 0.1 M 
sodium 
acetate 
4.6 2.0 M 
ammonium 
sulphate 
  None 0.1 M 
sodium 
citrate   
5.5 20 % w/v PEG 
3000 
  None 0.1 M 
imidazole 
8.0 10 % w/v PEG 
8000 
MDL 0.2 M 
potassium 
sodium 
tartrate 
0.1 M Na 
citrate 
5.6 2.0 M 
ammonium 
sulphate 
Table 3.2. List of screens which produced crystals that were frozen from P. aeruginosa co-
crystallisation experiments with pyruvate.  
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Fig. 3.16. Morpheus crystal dish containing P. aeruginosa omega transaminase protein 
crystals co-crystallised with gabaculine. A single diamond shaped crystal was seen. The 
condition was 90 mM NaF; NaBr; NaI, 100 mM Tris; Bicine, 30 % PEGMME 550; PEG 20K 
at pH 6.5.  
 
 
 
 
Fig. 3.17. JCSG plus crystal dish containing P. aeruginosa omega transaminase protein 
crystals co-crystallised with pyruvate. Numerous thin plate-like crystals were seen. The 
condition was 0.1 M sodium citrate, 20 % w/v PEG 3000 at pH 5.5.   
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Space group             C222    
Unit cell parameters            122.50 Å   192.0 Å   77.30 Å    90
o
  90
 o
  90
 o
 
 
Resolution                                    Overall     Low      High 
Low resolution (Å)                        29.51      29.51      2.32 
High resolution (Å)                       2.26        10.10      2.26 
Rmerge                                          0.156      0.060      0.702 
I/sigma                                           6.70       16.00       1.20 
Completeness (%)                         97.8        95.7        80.1 
Multiplicity                                    5.2          4.8          4.5 
 
Fig. 3.18. Statistics from X-ray diffraction at Diamond Synchrotron for gabaculine co-
crystallisation whose growth conditions were 90 mM NaF; NaBr; NaI, 0.1 M Tris; Bicine, 30 
% PEGMME 550; PEG 20000 at pH 6.5. 
 
 
Fig. 3.19. X-ray diffraction pattern for P. aeruginosa omega transaminase protein crystals co-
crystallised with gabaculine from conditions 90 mM NaF; NaBr; NaI, 100 mM Tris; Bicine, 
30 % PEGMME 550; PEG 20000 at pH 6.5. Despite being cryo-protected, ice rings were 
seen. Diffraction was to 2.2 Å resolution.  
 
 
 
 
 
 
 48 
Space group             P21212    
Unit cell parameters            111.96 Å   192.20 Å   76.70 Å    90
o
  90
 o
  90
 o
 
 
Resolution                                Overall    Low      High 
Low resolution (Å)                          30.05      30.05      1.84 
High resolution (Å)                          1.79       8.00        1.79 
Rmerge                                             0.137     0.053      0.716 
I/sigma                                             11.90      27.90      3.10 
Completeness (%)                            99.7        97.9       96.2 
Multiplicity                                      13.1        11.7       12.1 
 
Fig. 3.20. Statistics from X-ray diffraction at the Diamond Synchrotron for pyruvate co-
crystallisation. 
 
 
Fig. 3.21. X-ray diffraction pattern for P. aeruginosa omega transaminase protein crystals co-
crystallised with pyruvate from conditions 0.1 M sodium citrate, 20 % w/v PEG 3000 at pH 
5.5. There were no ice rings and data was collected to 1.86 Å resolution.   
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3.3. Structural Analysis 
3.3.1. Multiple Sequence Alignment 
A multiple sequence alignment was done to compare the differences in the primary 
sequence of the five omega transaminases. Based on structural studies the residue 
phenylalanine at position 89 was the target for mutagenesis in C. violaceum omega 
transaminase to allow it to utilise β-alanine as a substrate. This was still conserved in 
the sequence alignment (Fig. 3.22.) of the S. avermitilis and the P. aeruginosa omega 
transaminase which both have activity to β-alanine. However using the known 
structures of the C. violaceum and P. aeruginosa omega transaminases [24] F89 was 
displaced by one residue and did not superimpose between these two enzymes. 
Therefore it was difficult to infer the importance of F89 from the sequence alignment 
alone. The S. avermitilis omega transaminase was missing one of the tryptophan 
residues, at position 60, that is proposed to restrict the active site of other omega 
transaminases [25]. 
 
All the omega transaminases possessed the K288 (C. violaceum numbering) as was 
expected for they all bind PLP. D259 (C. violaceum numbering), responsible for 
hydrogen bonding with PLP, was present in all of the enzymes except for the               
D. geothermalis omega transaminase where it appeared to have been replaced by a 
proline residue.  
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CV2025.     MQKQR-----TTSQWRELDAAHHLHPFTDTASLNQAGARVMTRGEGVYLWDSEGNKIIDG 55 
KT2440.     MATPSKAFAIAHDPLVEADKAHYMHGYHVFDEHREQGALNIVAGEGAYIRDTHGNRFLDA 60 
PAO132.     MNQPLN---VAPPVSSELNLRAHWMPFSANRNFQKD-PRIIVAAEGSWLTDDKGRKVYDS 56 
SAV4551.    MTPQPN-----PQVGAAVKAADRAHVFHSWSAQELIDPLAVAGAEGSYFWDYDGRRYLDF 55 
DSM11300.   -----------------------MSERPLPPHLPLNRSRLIAPGP----VEVEPRVLLEL 33 
                                                 .  :. .      : . .   :  
 
CV2025.     MAGLWCVNVGYGRKDFAEAARRQMEELPFYNTFFKTTHPAVVELSSLLAEVTPAGFDRVF 115 
KT2440.     VGGMWCTNIGLGREEMALAIVDQVRQLAYSNPFSDMANDVAIELCQKLAQLAPGDLNHVF 120 
PAO132.     LSGLWTCGAGHSRKEIQEAVARQLGTLDYS-PGFQYGHPLSFQLAEKIAGLLPGELNHVF 115 
SAV4551.    TSGLVFTNIGYQHPKVVAAIQEQAASLTTFAPAFAVEARS--EAARLIAERTPGDLDKIF 113 
DSM11300.   AQPQIHHRTPQGIERLMEARAKLTRLLGDPYDAVITTSSGTGAFEGALISLTP------- 86 
                           .  *       *                    :    *        
 
CV2025.     YTNSGSESVDTMIRMVRRYWDVQGKPEKKTLIGRWNGYHGSTIGGASLG-GMKYMHEQGD 174 
KT2440.     LTTGGSTAVDTAYRLIQYYQNCRGKPHKKHIIARYNAYHGSTTLTMSIGNKAADRVPEFD 180 
PAO132.     FTGSGSECADTSIKMARAYWRLKGQPQKTKLIGRARGYHGVNVAGTSLG-GIGGNRKMFG 174 
SAV4551.    FTNGGADAIEHAVRMARIHT---GRP---KVLSAYRSYHGGTQQAVNIT-GDPRRWASDS 166 
DSM11300.   --EGGRVVNAQAGKFSERWG-------------DMSERLGYETVRVARPWGDLLDPEEVA 131 
               .*        :: .                      *                     
 
CV2025.     LPIPGMAHIEQPWWYKHGKDMTPDEFGVVAARWLEEKILEIGADKVAAFVGEPIQGAGGV 234 
KT2440.     YHHDLIHHVSNPNPYRAPDDMDEAEFLDFLVAEFEDKILSLGADNVAAFFAEPIMGSGGV 240 
PAO132.     QLMDVDHLPHTLQPGMAFTRGMAQTGGVELANELLKLIELHDASNIAAVIVEPMSGSAGV 234 
SAV4551.    ASAGVVHFWAPYLYRSRFYAETEQQECERALEHLETTIAFEGPGTIAAIVLETVPGTAGI 226 
DSM11300.   DAARNAHTLLITHSETSTGALHDLAAIAQAAKAQNPDLVIIADCITSYGVAELRPAAWGV 191 
                                                 :        :  . *   .: *: 
 
CV2025.     IVPPATYWPEIERICRKYDVLLVADEVICGFGRTGEWFG-HQHFGFQPDLFTAAKGLSSG 293 
KT2440.     IIPPEGYFQRMWQLCQTYDILFVADEVVTSFGRLGTFFASEELFGVTPDIITTAKGLTSA 300 
PAO132.     LVPPVGYLQRLREICDQHNILLIFDEVITAFGRLGTYSG-AEYFGVTPDLMNVAKQVTNG 293 
SAV4551.    MVPPPGYLAGVRELCDKYGIVFVLDEVMAGFGRTGEWFA-ADLFDVTPDLMTFAKGVNSG 285 
DSM11300.   DVIVSGSQKGAATPPG-LGFVLLSPEVQERMIPT-------PQRGFYLDLTRELKGQKAG 243 
             :                ..:::  **   :             ..  *:    *  . . 
 
CV2025.     YLPIGAVFVGKRVAEGLI---AGGD---FNHGFTYSGHPVCAAVAHANVAALRDEGIVQR 347 
KT2440.     YLPLGACIFSERIWQVIA---EPGKGRCFTHGFTYSGHPVCCTAALKNIEIIEREQLLDH 357 
PAO132.     AVPMGAVIASSEIYDTFMNQALPEHAVEFSHGYTYSAHPVACAAGLAALDILARDNLVQQ 353 
SAV4551.    YVPLGGVAISGKIAETFG-------KRAYPGGLTYSGHPLACAAAVATINVMAEEGVVEN 338 
DSM11300.   NTPQTPAIN---LISALS--------------LALDRLLAVPLEVLWAEKRRQANALIAA 286 
              *         : . :                : .                  : ::   
 
CV2025.     VKDDIGPYMQKRWRETFSRFEHVDDVRGVGMVQAFTLVKNKAKRELFPDFGEIGTL---- 403 
KT2440.     VN-DVGSYLEQRL-QSLRDLPLVGDVRCMKLMACVEFVANKASKALFADEVNIGER---- 411 
PAO132.     SA-ELAPHFEKGL-HGLQGAKNVIDIRNCGLAGAIQIAPRDGDPTVRPFEAGM------- 404 
SAV4551.    AANLGARVIEPGLRELAERHPSVGEVRGVGMFWALELVKDRETREPLVPYNAAGEANAPM 398 
DSM11300.   GEALGAPAWAARTSPAVAVLKPPAPLTGRQVAARLAAMGQRALPGQAPYEDAVFRVS--- 343 
                 .                   :    :   .                          
 
CV2025.     --CRDIFFRNNLIMRACGDHIVSAPPLVMTRAEVDEMLAVAERCLEEFEQTLKARGLA-- 459 
KT2440.     --IHSKAQEKGLLVRPIMHLNVMSPPLIITHAQVDEIVETLRQCIIETARELTALGLYQG 469 
PAO132.     -----KLWQQGFYVRFGGDTLQFGPTFNARPEELDRLFDAVGEALNGIA----------- 448 
SAV4551.    AAFGAAAKANGLWPFINMNRTHVVPPCNVTEAEAKEGLAALDAALSVADEYTV------- 451 
DSM11300.   ----TLGYADRYDALGIAGMLEDAFASLGVPFERGAAVQAAWRVLGEERREMAGCEAR-- 397 
                     .               .      :    . .    :                
 
CV2025.     - 
KT2440.     R 470 
PAO132.     - 
SAV4551.    - 
DSM11300.   - 
 
Fig 3.22. Sequence alignment for C. violaceum (CV2025), P. aeruginosa (PA0132), S. 
avermitilis (SAV4551), P. putida (KT2440) and D. geothermalis (DSM11300) omega 
transaminases using ClustalW from EBI Database. "*" means that the residues in that column 
are identical for all the sequences in the alignment. ":" means that there are conserved 
substitutions based on the properties of the amino acids. "." means that semi-conserved 
substitutions are observed. Conserved residues as discussed  in 3.3.1 are highlighted in red. 
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3.3.2. Homology Modelling Analysis 
Through homology modelling, insight into the structure of the S. avermitilis omega 
transaminase can be determined. The template used for the homology modelling was 
the C. violaceum omega transaminase holoenzyme. The model was made using MOE 
(Molecular Operating Environment) with the amber99 force field. The final structure 
that was made had an RMSD of 0.884 Å indicating there was a strong similarity 
between the homology model and the template structure. Fig. 3.23. shows the two 
structures superimposed upon one another. Analysis of the active site (Fig. 3.24.) 
showed that K288 and F89 were in the same locations as those on the C. violaceum 
omega transaminase. The major difference that was observed was the absence of the 
R416 residue. Examination of the strand region it should be located on revealed that 
there was no carboxyl binding region present on it. The complete absence of this key 
residue seems unlikely as it is required for substrate binding. The most probable 
reason for this is that the carboxyl binding group is present on a different substructure 
within the active site. Close to where the R416 should be located was another arginine 
residue on a nearby loop region, R405, which seemed to be the most probable 
candidate since there was 6 Å distance between the closest nitrogen groups (Fig. 
3.24.). 
 
 
Fig. 3.23. S. avermitilis omega transaminase homology model, shown in red. The template,    
C. violaceum omega transaminase, is superimposed upon it and displayed in green. Both 
chains show high similarity to one another with a root-mean-square deviation of 0.884 Å. 
Image made using PyMOL [26]. 
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Fig. 3.24. Homology modelling using MOE to show difference in key arginine residues using 
PyMOL [26]. PLP is displayed in yellow and the F89 is displayed in black. The C. violaceum 
omega transaminase chain is shown as green with R416 displayed in blue. The S. avermitilis 
omega transaminase chain and R405 are shown in red. The distance between the closest 
nitrogen groups of R405 and R416 was 6 Å. 
Phe89 
Arg405 
Arg416 
PLP 
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Fig. 3.25. Ramachandran plot of the S. avermitilis omega transaminase homology model 
using the software Procheck [43]. 
 
3.3.3. Structural Refinement of Mutant C. violaceum omega transaminase 
An R factor of 0.2014 and a free R factor of 0.2376 were achieved through structural 
refinement with COOT [40] and REFMAC [41]. This subsequently proved the mutant 
to have the same overall folding pattern as the native enzyme as is displayed in Fig. 
3.26. which displays the F89A mutant in red superimposed upon the native C. 
violaceum omega transaminase. The key amino acid residues remained conserved 
within the active site with very little difference in their positions. The mutation of F89 
to A89 can be seen in Fig. 3.27. The mutation of F89 can clearly be seen to be 
successful and loss of the phenylalanine side chain clearly provided more room within 
the active site. It resulted in a shift in the Cα backbone as is shown in Fig. 3.27. which 
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allowed even more room for substrate binding within the active site. The R416 side 
chain was seen to move closer to the location where the phenylalanine side chain was 
once located which indicated it now possessed greater flexibility since it can now 
inhabit space it was previously unable to.  
 
Using COOT [40] β-alanine was placed within the active site to determine the 
viability of it binding to the active site after mutation of F89 (Fig. 3.29.). Although 
there was now greater flexibility of R416 to bind and assume an orientation for 
catalytic activity with the substrate, there seemed to be a phenylalanine at position 88 
which could prevent it binding. The side chain appeared to prevent the β-alanine from 
attaining a position where it could bind to the PLP and R416. Testing of the F89A 
mutant in an activity assay would determine if the single amino acid residue change 
was adequate to allow β-alanine to be utilised as a substrate.  
 
Fig. 3.26. F89A mutant, shown in red, superimposed by the native C. violaceum omega 
transaminase, shown in green using PyMOL [26]. The overall fold of the protein remained 
mainly unaltered by the mutation. 
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Fig. 3.27. The 2Fo-Fc electron density map is shown in blue contoured at 1 sigma level 
with the model of the F89A mutant protein fitted in (carbons are shown in green). Also shown 
is the superimposed refined structure of the native protein (carbons are shown in 
yellow).Mutation of F89 to A89 caused a shift in the loop region it is on away from the active 
site and provided more room for substrate binding. The R416 was seen to move closer to 
where the phenylalanine side chain used to be, indicating there to be greater flexibility. Image 
made using COOT [40]. 
 
 
Fig. 3.28. PyMOL image displaying the shift in the loop region and the altered position of the 
R416 in the F89A mutant, shown in red, compared to the holoenzyme structure, shown in 
green [26]. 
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Fig. 3.29. β-alanine placed within the active site of F89A mutant using COOT [40] and image 
made with PyMOL [26]. The purple chain represents the native enzyme, the green chain 
represents F89A mutant. F88 could prevent binding of the substrate due to steric hindrance.  
 
3.4. Activity Assays 
HPLC and tetrazolium salt based assays were carried out at UCL with Professor John 
Ward and Dr Nina Richter.  
 
Results from HPLC assays are shown in Table. 3.3. with the omega transaminase 
CV2025 from C. violaceum in the form of a crude lysate as control. MBA assays were 
performed to confirm that the omega transaminase had retained its activity. An 
increase in acetophenone was observed which indicated that the F89A mutant omega 
transaminase still possessed enzymatic activity. Samples at 0.5 mg of enzyme tested 
for activity towards β-alanine showed no decrease in acetophenone concentration 
compared to the blank. A second sample at a higher concentration of 2 mg of enzyme 
was made, however this failed to provide any decrease in acetophenone 
concentrations compared to the blank either.  
 
As the equilibrium lied in favour of acetophenone production, the HPLC assay was 
attempting to drive the reaction in an unfavourable direction with none of the products 
removed to help maintain conversion. This might have given a negative result if the 
F89A omega transaminase had very low activity towards β-alanine. So a 
colourimetric assay was performed by utilising the conversion of NAD
+
 to NADH by 
an Alanine Dehydrogenase as it converted alanine to pyruvate. This removed one of 
β-alanine 
Phe88 
Arg416 
PLP 
Phe88 
PLP 
Arg416 
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the products and regenerated one of the substrates to ensure the reaction was not 
halted by reaching equilibrium. Analysis of the wells showed no colour change had 
occurred within the wells containing the F89A mutant. The only colour change 
observed was in the C. violaceum omega transaminase well, however since this was a 
crude lysate there are most likely many NAD
+  NADH systems within the sample. 
 
A second colourimetric assay was performed as the previous one had was still under 
development at UCL. This one was based on an L-amino acid oxidase converting the 
alanine back into pyruvate thus regenerating the amine acceptor, producing hydrogen 
peroxide. This product is utilised by the horseradish peroxidase to produce a quinone-
imine dye from TBHBA and 4-AAP. After incubating overnight at room temperature 
a subtle colour change was visible as is seen in Fig. 3.30. with three repeats of both 
the wild type CV2025 and the F89A mutant. The bottom two wells contained the 
positive and negative controls. The negative control had an absorbance of 0.7289. The 
CV2025 wild type wells had mean absorbances of 0.7337, 0.7379 and 0.7300, none of 
which were significantly higher than the negative control. The F89A mutant showed a 
slightly different colour than that seen in both the wild type and negative control. Its 
absorbance's were 0.7689, 0.7645 and 0.7862. This small but consistent increase in 
absorption indicated there to be a small increase in alanine being produced by the 
F89A mutant compared to the blank and wild type based on the visual colour change. 
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Assay Sample Protein 
Concentration/mg 
Incubation 
Time/hours 
Area of 
Peak 
Acetophenone 
conetration/mM 
MBA Blank 0 0 9699 0.006 
β-alanine  Blank 0 0 15881114 9.41 
MBA Blank 0 0.5 27476 0.02 
MBA F89A 0.5 0.5 7307780 4.33 
MBA CV2025 0.5 0.5 624539 0.370033285 
β-alanine  Blank 0 0.5 15540892 9.21 
β-alanine  F89A 0.5 0.5 16188485 9.59 
β-alanine  CV2025 0.5 0.5 16648912 9.864318482 
β-alanine  Blank 0 4 15671678 9.29 
β-alanine  F89A 0.5 4 15792490 9.36 
β-alanine  CV2025 0.5 4 15502498 9.185079334 
β-alanine  Blank 0 21 15027740 8.90 
β-alanine  F89A 0.5 21 14632531 8.67 
β-alanine  CV2025 0.5 21 14454644 8.564236027 
β-alanine  Blank 0 0 16323606 9.67 
β-alanine  Blank 0 1 15807653 9.37 
β-alanine  F89A 2 1 15742973 9.33 
β-alanine  CV2025 2 1 15814363 9.369856314 
β-alanine  Blank 0 17 13288295 7.87 
β-alanine  F89A 2 17 13843313 8.20 
β-alanine  CV2025 2 17 13769354 8.158208365 
Table. 3.3. Results from the HPLC assays.  
 
 
 
 
Fig. 3.30. Image of microtiter plate from amino acid oxidase/horseradish peroxidase linked 
assay. Bottom two wells contained the negative and positive controls, the latter of which 
clearly possessed a significant difference in colour. F89A mutant with the naked eye alone 
appeared to have a slightly different colour. 
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3.5. Differential Scanning Fluorometry 
Fig. 3.31. shows the Tm values for each well of the differential scanning fluorometry 
trials with S. avermitilis omega transaminase as determined by the Boltzmann 
equation within Prism (GraphPad). Wells G7, G8 and G9 which contained potassium 
acetate pH 5.8 were empty due to anomalous Tm values of 140.6
o
C, 95.51
o
C and 
212.8
o
C respectively. When examining the graphs themselves the curves appeared to 
be similar to the others with no obvious errors and no reason for these values could be 
found when examining the data put into Prism. This would need to be repeated to 
determine the Tm for this buffer.  
 
Tris at pH 7.5 was used as a control (Fig 3.32.). The graph showed two peaks, each 
one indicating the unfolding of a different subunit of the dimer. The average Tm value 
was 55
o
C which was close to the other two Tris buffers, pH 7 had an average Tm of 
56.6
o
C and pH 8 had a Tm of 58.8
o
C. These were considerably lower than the other 
average Tm values for the rest of the buffers tested where the majority ranged 
between 68
o
C and 71
o
C. Apart from the Tris buffers, Bis-Tris propane at pH 8 had the 
lowest average Tm value at 66
o
C, but even this was much higher than the three Tris 
buffers tested. The highest average Tm was for MES at pH 6 whose value was 
calculated to be 75.8
o
C. The graph in Fig. 3.33. showed a significant decrease in the 
amount of unfolding of the first subunit as the first peak in comparison with the first 
was much smaller signifying an increase in the thermodynamic stability of the 
protein. This average only took into account two of the datasets as one was 71.1
o
C 
which was 4.28
o
C lower than the second lowest value and possibly an outlier due to 
the difference from the other two. The second and third highest after this was 
potassium phosphate pH 6.5 with an average Tm of 72.5
o
C and pH 6 with an average 
Tm of 72.4
o
C. 
 
Unfortunately these results are not reliable as the Boltzmann equation used is valid 
only for single transitions. A double transition is seen here from the unfolding of each 
subunit of the dimer. As this is the case the analysis method used is limited and other 
forms of analysis must be considered in the future such as calculating the first or 
second derivatives.  
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Fig. 3.31. Bar chart showing different Tm values for each well as calculated by Prism. Wells 
G7-G9 are not shown due to anomalous results. Wells listings are on the Y axis, temperature 
is on the X axis in degrees Centigrade.  
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Fig. 3.32. Graph showing change in fluorescence which corresponds to the unfolding of the 
protein for the control, Tris at pH 7.5. Dark blue data considered unreliable.  
 
Fig. 3.33. Graph showing change in fluorescence which corresponds to the unfolding of the 
protein for MES at pH 6. Dark blue data considered unreliable.  
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Chapter 4 - Discussion 
The inability of the D. geothermalis omega transaminase to bind to Nickel columns 
was most likely the result of the histidine tag becoming buried within the protein 
itself. Given time an alternate means of purification might be found, for the only thing 
that stopped attempts at purification was lack of time. The presence of the His-tag 
would have to be confirmed by means of Nickel chromatography with urea or 
guanidinium chloride to denature the protein and see if binding occurs. This would 
confirm whether the His tag has been lost or buried. If the latter were to be proved 
true then a new construct would have to be made with the His-tag located at the C-
terminal of the protein. 
 
The processing of X-ray data obtained from the P. aeruginosa omega transaminase 
proved to be a challenge due to incorrect assignment of the space group. This was 
probably due to a pseudo translation, tiny rotational or conformational differences 
causing modulation of intensities and leading to the doubling in size of the unit cell. 
Also the assignment of a space group was made difficult by the protein possessing a 
two fold proper axis that is not crystallographic, parallel to a screw axis that is 
crystallographic. The fact that the program Zanuda gave a space group of P21212 
confirms this, as here the two fold proper axis is considered crystallographic so a 
greater value in correlation calculations is obtained. (All work done under Dr Michail 
Isupov) 
 
The failure to get the structure of P. aeruginosa omega transaminase with pyruvate 
within the active site was disappointing. Although acceptor substrate-pyridoxal 
phosphate intermediates were predicted to exist in the 1960's, no one so far has 
managed to observe them with one exception. The concentration of sodium pyruvate 
used was very high at 30 mM and near the limit of what could be used so using a 
higher concentration of pyruvate is not an option. This along with the data from the 
crystal soaks indicates that trapping a stable complex of PLP with pyruvate in omega 
transaminases is difficult. The data that was obtained by Dr Christopher Sayer [24] 
with C. violaceum transaminase where pyruvate is seen within the active site appears 
to be unique and difficult to repeat with others omega transaminases.   
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It is unknown whether gabaculine successfully co-crystallised with P. aeruginosa 
omega transaminase due to the poor quality of the data retrieved. Given what is 
known about the binding of gabaculine in previous work with the C. violaceum omega 
transaminase, it is highly likely that there was binding to the P. aeruginosa omega 
transaminase since gabaculine is such a highly potent inhibitor. It was concluded that 
the quality of the crystal used in the data collection prevented us from seeing this. 
Improved crystals were taken to the Diamond Synchrotron in March. 
 
During the work with P. aeruginosa omega transaminase several new crystal forms 
were observed. The crystals were thin which made it hard to ensure that they were hit 
with the X-ray beam throughout all 360
o
 of data collected, however they proved to 
provide high resolution data.  
 
The failure of P. putida omega transaminase to crystallise properly is not uncommon 
in any crystallisation trial. It might be that one of the new screens that became 
available near the end of the experiment, the Morpheus and MIDAS, would 
successfully crystallise the protein.   
 
The mutation of F89 to A89 in the C. violaceum omega transaminase was shown 
clearly in the crystal structure after structural refinement. The overall structure was 
conserved in the mutant protein. The objective of the mutation was to create more 
room in the active site and greater flexibility of the carboxyl binding group R416, 
both of which were observed. The backbone chain on which the A89 was present 
showed movement away from the active site which, along with the loss of the 
phenylalanine side chain, would allow more space for substrates to bind. Also the 
R416 showed movement towards the location where the F89 side chain had been, 
indicating the arginine side chain could now occupy a conformation which previously 
would have previously been hindered. However from looking at the active site with β-
alanine placed within it suggests the possibility that this mutation alone might be 
inadequate for activity with this substrate. Testing with both HPLC and tetrazolium 
salt based high-throughput assays both showed there was no detectable activity 
towards β-alanine. However the amino acid oxidase/horseradish peroxidase linked 
assay showed there to be some small difference when left for a long period of time 
which could indicate that there is a small amount of activity towards β-alanine due to 
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the F89A mutation. This might have been previously undetected as the HPLC assay 
was going against the equilibrium and the tetrazolium salt based high-throughput 
assay was still being established at the time and had not been given as long to run. 
While the activity is not as high as was expected initially, there does appear to be 
limited success in endowing the ability of the mutant to utilise β-alanine as a 
substrate.  
 
So although the mutation was based upon the P. aeruginosa omega transaminase 
which utilises β-alanine as a substrate, it is clear that this is insufficient to provide any 
significant activity and further comparison between the two structures is required. A 
mutation of the F88 might go some way to allow binding of β-alanine as docking 
experiments indicate it might cause steric hindrance towards binding larger substrates 
such as β-alanine. 
 
The differential scanning fluorometry experiment with S. avermitilis omega 
transaminase clearly showed that the standard Tris buffer that had been used was by 
far the worst possible buffer to use when compared to those that were screened. It is 
unlikely that this was due to the pH changes that Tris undergoes when the temperature 
is altered as the pH 8 Tris buffer would have had a Tm over 10
o
C higher than the pH 
7.5. This is concluded as a temperature change from 25
o
C to 37
o
C results in a change 
in pH of approximately 0.3 for each of the pH's meaning an increase of 0.5 pH units 
should result in a considerably higher Tm if denaturing is due solely to an increase in 
acidity. With a difference in Tm of 20
o
C between Tris at pH 7.5 and MES at pH 6, it 
is possible that ordered crystals might be obtained should the buffer be changed to 
this. This is due to the large increase in thermodynamic stability and under these 
conditions which should allow more ordered crystals to be grown which diffract to 
high resolution.  
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Chapter 5 - Conclusion 
5.1. Summary of Work 
Crystallising P. aeruginosa omega transaminase with pyruvate does not appear 
possible for both crystal soaking and co-crystallisation with pyruvate at a high 
concentration failed. It would seem unlikely therefore to be able to repeat the 
experiment where it was seen within the active site of the C. violaceum omega 
transaminases.  
 
From what has been seen so far, differential scanning fluorometry appears to be a 
potential tool in protein crystallography. The results from it appear to be positive for it 
showed the current Tris buffer to stabilise the S. avermitilis omega transaminase 
protein the least of those tested and would explain the disordered crystals that have 
been obtained up until now. To confirm this, crystallisation trials will need to be 
performed with one of the buffers with the highest Tm values and see if there is any 
improvement in crystal disorder.  
 
The F89A mutant C. violaceum omega transaminase had some success in using β-
alanine as a substrate but only at a slow rate. It is clear that increasing the flexibility 
of the carboxyl binding group R416 and creating more room in the active site where 
the F89 residue was located seems to allow a small amount of activity towards β-
alanine but it is insufficient to confer full activity towards this substrate. Further 
mutations will be necessary to allow optimal use of β-alanine. An amino acid target 
identified in this project would be the F88 residue, whose side chain is located close 
to the location where β-alanine would need to be located upon binding to the R416 to 
also bind the PLP co-factor.  
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5.2. Future Work 
 Crystallising S. avermitilis omega transaminase within one of the buffers that 
provided the highest Tm values from the differential scanning fluorometry to 
see if there is any improvement the crystals formed.  
 The F89A mutant from C. violaceum omega transaminase should be screened 
for changes in activity towards other substrates and see what effects it has. 
Also more mutants will need to be generated if β-alanine is to be used as a 
substrate by this enzyme. 
 The D. geothermalis omega transaminase needs a new protocol to be made for 
the purification of the enzyme without the standard Nickel affinity 
chromatography. Hydrophobic interaction chromatography has already proven 
a viable step. All that is most likely required is an alternative to ion exchange 
chromatography as a purification step before gel filtration chromatography. A 
new construct with the His-tag on the C-terminal end of the protein could be 
considered also. 
 The remaining crystals of P. aeruginosa omega transaminase from the co-
crystallisation trials need to go to the Diamond Synchrotron for X-ray 
diffraction to try and find a crystal from the gabaculine co-crystallisation 
experiment that will diffract well.  
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